PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Ian J Majewski Sherene Loi Valentina Guarneri Emilio Bria Carsten Denkert Pierfranco Conte René Bernards |
| Publication date | May 13, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |